Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludarabine Phosphate

FDA-approved product (injectable, injection), marketed as Fludara, Fludarabine Phosphate, Oforta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fludarabine Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Purine analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludarabine Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludarabine Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

    NCT06149403 · start 2023-12-11

    Registered record
    Registry ID
    NCT06149403
    Conditions
    MPS-IH (Hurler Syndrome)
    Interventions
    Experimental: OTL-203; Active Comparator: Allo-HSCT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-12-11
    Completion
    2031-03
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMPS-IH (Hurler Syndrome)
    InterventionExperimental: OTL-203; Active Comparator: Allo-HSCT
    PhasePhase 3
    Registry statusActive not recruiting

  • JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

    NCT06045585 · start 2023-08-18

    Registered record
    Registry ID
    NCT06045585
    Conditions
    Relapsed or Refractory B-cell Lymphoma
    Interventions
    infusion of JY231 injection
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2023-08-18
    Completion
    2025-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory B-cell Lymphoma
    Interventioninfusion of JY231 injection
    PhaseEarly phase 1
    Registry statusUnknown

  • Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

    NCT04354025 · start 2023-06-30

    Registered record
    Registry ID
    NCT04354025
    Conditions
    Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia
    Interventions
    Cytokine induced memory-like NK cells; Fludarabine; Ara-C; G-CSF; Interleukin-2; Leukapheresis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-06-30
    Completion
    2028-07-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia
    InterventionCytokine induced memory-like NK cells; Fludarabine; Ara-C; G-CSF +2 more
    PhasePhase 2
    Registry statusWithdrawn

  • E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

    NCT05686226 · start 2023-03-07

    Registered record
    Registry ID
    NCT05686226
    Conditions
    Cervical Cancer; Throat Cancer; Oropharynx Cancer; Anal Cancer; Vulva Cancer; Vaginal Cancer; Penile Cancer; Metastatic Cancer; HPV-Related Malignancy; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Squamous Cell Carcinoma; HPV-Related Adenocarcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Associated Vaginal Adenocarcinoma; HPV-Related Adenosquamous Carcinoma; HPV-Related Endocervical Adenocarcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Penile Squamous Cell Carcinoma; HPV-Related Vulvar Squamous Cell Carcinoma; HPV Positive Rectal Squamous Cell Carcinoma
    Interventions
    E7 TCR-T cells; Aldesleukin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-03-07
    Completion
    2027-01-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Cancer; Throat Cancer; Oropharynx Cancer; Anal Cancer +17 more
    InterventionE7 TCR-T cells; Aldesleukin
    PhasePhase 2
    Registry statusRecruiting

  • Chidamide Bridging for CAR-T Therapy

    NCT05370547 · start 2022-05-25

    Registered record
    Registry ID
    NCT05370547
    Conditions
    Non Hodgkin's Lymphoma
    Interventions
    Chidamide; Fludarabine and cyclophosphamide; Anti-CD19 CAR-T cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-05-25
    Completion
    2025-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Hodgkin's Lymphoma
    InterventionChidamide; Fludarabine and cyclophosphamide; Anti-CD19 CAR-T cells
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

    NCT04539366 · start 2022-01-25

    Registered record
    Registry ID
    NCT04539366
    Conditions
    Recurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Neuroblastoma; Refractory Childhood Osteosarcoma; Refractory Neuroblastoma; Refractory Osteosarcoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cyclophosphamide; Echocardiography Test; Fludarabine Phosphate; GD2-CAR-expressing Autologous T-lymphocytes; Imaging Procedure; Magnetic Resonance Imaging of the Heart; Multigated Acquisition Scan; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2022-01-25
    Completion
    2040-12-31
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma +4 more
    InterventionBiopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy +8 more
    PhasePhase 1
    Registry statusSuspended

  • CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

    NCT04787263 · start 2021-03-04

    Registered record
    Registry ID
    NCT04787263
    Conditions
    Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma
    Interventions
    CD19-CAR_Lenti T cell
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2021-03-04
    Completion
    2038-03-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma
    InterventionCD19-CAR_Lenti T cell
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Natural Killer-cell Therapy for Acute Myeloid Leukemia

    NCT04347616 · start 2020-12-03

    Registered record
    Registry ID
    NCT04347616
    Conditions
    Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, Relapsed, Adult
    Interventions
    UCB-NK cells; IL-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-12-03
    Completion
    2026-01-30
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, Relapsed, Adult
    InterventionUCB-NK cells; IL-2
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

    NCT04196413 · start 2020-06-04

    Registered record
    Registry ID
    NCT04196413
    Conditions
    Glioma of Spinal Cord; Glioma of Brainstem
    Interventions
    GD2 CAR T cells; Fludarabine; Cyclophosphamide; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2020-06-04
    Completion
    2043-07-31
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma of Spinal Cord; Glioma of Brainstem
    InterventionGD2 CAR T cells; Fludarabine; Cyclophosphamide; Rituximab
    PhasePhase 1
    Registry statusRecruiting

  • A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

    NCT04426669 · start 2020-05-15

    Registered record
    Registry ID
    NCT04426669
    Conditions
    Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer, Gastrointestinal; Gastrointestinal Cancer; Colo-rectal Cancer; Pancreatic Cancer; Gall Bladder Cancer; Colon Cancer; Esophageal Cancer; Stomach Cancer
    Interventions
    Cyclophosphamide; Fludarabine; Tumor-Infiltrating Lymphocytes (TIL); Aldesleukin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2020-05-15
    Completion
    2026-01-22
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer, Gastrointestinal +7 more
    InterventionCyclophosphamide; Fludarabine; Tumor-Infiltrating Lymphocytes (TIL); Aldesleukin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Stem Cell Transplantation in Crohn's Disease

    NCT04224558 · start 2019-11-15

    Registered record
    Registry ID
    NCT04224558
    Conditions
    Crohn Disease
    Interventions
    Mesna; Cyclophosphamide; Filgrastim; Apheresis catheter placement; Leukapheresis; Fludarabine; Methylprednisolone; Diphenhydramine; Acetaminophen; anti-thymocyte globulin (rabbit); lymphocyte immune globulin; Peripheral Blood Stem Cell Infusion; Cytoxan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-11-15
    Completion
    2027-09-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn Disease
    InterventionMesna; Cyclophosphamide; Filgrastim; Apheresis catheter placement +9 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

    NCT03622788 · start 2019-08-08

    Registered record
    Registry ID
    NCT03622788
    Conditions
    Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Aplastic Anemia; Bone Marrow Failure; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Plasma Cell Myeloma
    Interventions
    Anti-Thymocyte Globulin; Cyclophosphamide; Cytokine-treated Veto Cells; Fludarabine; Peripheral Blood Stem Cell Transplantation; Total-Body Irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2019-08-08
    Completion
    2027-12-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Aplastic Anemia; Bone Marrow Failure +9 more
    InterventionAnti-Thymocyte Globulin; Cyclophosphamide; Cytokine-treated Veto Cells; Fludarabine +2 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

    NCT03913026 · start 2019-04-01

    Registered record
    Registry ID
    NCT03913026
    Conditions
    High Risk Hematologic Malignancy; Cord Blood Transplant
    Interventions
    Transplant with an expanded ECT-001 cord blood
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-01
    Completion
    2027-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk Hematologic Malignancy; Cord Blood Transplant
    InterventionTransplant with an expanded ECT-001 cord blood
    PhasePhase 2
    Registry statusActive not recruiting

  • Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

    NCT03236129 · start 2018-02-22

    Registered record
    Registry ID
    NCT03236129
    Conditions
    Hematological Malignancies; Regulatory T Cell Depletion; Relapse
    Interventions
    T-reg depleted DLI; Standard DLI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-02-22
    Completion
    2026-02
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancies; Regulatory T Cell Depletion; Relapse
    InterventionT-reg depleted DLI; Standard DLI
    PhasePhase 3
    Registry statusUnknown

  • Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

    NCT03263559 · start 2017-10-03

    Registered record
    Registry ID
    NCT03263559
    Conditions
    Sickle Cell Disease
    Interventions
    Haploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa; Fludarabine; Cyclophosphamide; Total Body Irradiation; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-03
    Completion
    2025-01-29
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease
    InterventionHaploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa +4 more
    PhasePhase 2
    Registry statusCompleted